Clinical trials: Liver Inflammation
Chronic Hepatitis C
The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects
A Phase Ib/IIa, Single Center, Randomized, open, Sofosbuvir-controlled, Multiple Ascending Dose Study to Access the Tolerability，Pharmacokinetics and Pharmacodynamics of HEC110114 Tablets in HCV-infected Subjects
- Trial name
- HEC110114 (NCT04202952)
- Testing
- HEC110114 Tablet, Sofosbuvir Tablet
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Chronic Hepatitis C Infection
Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients
The primary objective of this protocol is to study the effect of the standard of care in hepatitis C (pegylated interferon and ribavirin) associated with therapeutic vaccine TG4040 on the viral load of treatment-naïve patients…
- Trial name
- HCVac (NCT01055821)
- Testing
- pegylated interferon and ribavirin, TG4040 + SOC
- Where
- Germany
- Volunteers
- 140 people
- Sponsor
- Transgene
Fibrosis, Hepatitis C Chronic
Pirfenidone, an Antifibrotic and Antiinflammatory Drug
The aim of this study was to assess whether two-year treatment with Pirfenidone influence necro-inflammation, fibrosis and steatosis in patients with chronic hepatitis C.
- Trial name
- NCT02161952
- Testing
- Pirfenidone
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Guadalajara
Diphtheria, Hepatitis B
Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants
In this study, infants will be randomly allocated into three groups: one group of subjects will receive DTPa-HBV-IPV/Hib vaccine (new formulation) the second group of subjects will receive DTPa-HBV-IPV/Hib vaccine (current…
- Conditions
- Diphtheria, Hepatitis B, Poliomyelitis, Tetanus
- Trial name
- NCT00320463
- Testing
- DTPa-HBV-IPV/Hib vaccine
- Where
- 4 sites in Russia
- Volunteers
- 415 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis C
HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity
Objective: The goal is to improve peginterferon sensitivity in previous poor responders. "Sensitivity" here means the host's ability to kill more HCV.
- Trial name
- NCT01377909
- Testing
- statin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Bader, Ted, M.D.
Chronic Hepatitis B
Sustained HBsAg and Viral Response in Patients Achieved HBsAg Loss by Interferon Treatment
Chronic hepatitis B (CHB) is a serious liver disease worldwide, and the leading cause of cirrhosis and hepatocellular carcinoma (HCC).HBsAg loss/seroconversion is considered to be the ideal endpoint of antiviral therapy in both…
- Trial name
- NCT02336399
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Beijing Ditan Hospital
HIV Infections, Hepatitis B
Hepatocellular Carcinoma in HIV-infected Individuals in Asian Population
This is a retrospective study, all HIV-infected individuals followed up at the three designated HIV clinics in Hong Kong with and without HBV and/or HCV co-infection will be included in the analysis.
- Conditions
- HIV Infections, Hepatitis B, Hepatitis C, Hepatocellular Carcinoma
- Trial name
- NCT03702998
- Where
- Hong Kong
- Volunteers
- 3,900 people
- Sponsor
- Chinese University of Hong Kong
Chronic Hepatitis B
A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
This is an open-label study evaluating multiple doses of GS-7340 versus Tenofovir disoproxil fumarate (TDF).
- Trial name
- NCT01671787
- Testing
- GS-7340, Tenofovir disoproxil fumarate
- Where
- 19 sites in United States, Australia and 3 more
- Volunteers
- 51 people
- Sponsor
- Gilead Sciences
Non-Alcoholic Fatty Liver Disease, Obese
Fatty Liver in Obesity: Long-lifestyle Follow-up (FLiO)
Non-alcoholic fatty liver disease (NAFLD) is a condition of excessive hepatic lipid accumulation in subjects that consume less than 20g ethanol per day, without other known causes as drugs consumption or toxins exposure.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obese, Overweight
- Trial name
- FLiO (NCT03183193)
- Testing
- Control diet, FLiO diet
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Hepatitis C
Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment
The main objective of this study is to investigate the influence of mild, moderate and severe renal impairment on the pharmacokinetics and safety of BI 201335 in comparison to a control group with normal renal function after…
- Trial name
- NCT01580306
- Testing
- BI 201335
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity, Atherosclerosis
Observational Study of Early Metabolic and Vascular Changes in Obesity
To work against the increasing burden of obesity, the STYJOBS / EDECTA (STYrian Juvenile OBesity Study / Early DetECtion of Atherosclerosis) project was started at the Medical University of Graz in 2003.
- Conditions
- Obesity, Atherosclerosis, Inflammation, Adiponectin Deficiency
- Trial name
- STYJOBS (NCT00482924)
- Testing
- Lifestyle intervention
- Where
- Austria
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Chronic Hepatitis b
Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection
This is a randomized, open label, multicenter Phase 2 study investigating the safety and antiviral activity of AB-729 in combination with ongoing NA therapy and short courses of Peg-IFNα-2a in subjects with CHB.
- Trial name
- NCT04980482
- Testing
- AB-729, Peg-IFNα-2a
- Where
- 17 sites in United States, Australia and 5 more
- Volunteers
- 43 people
- Sponsor
- Arbutus Biopharma Corporation
Hepatitis B, Chronic
A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B
This study is a long-term post-treatment follow-up to study WV19432, which evaluated the efficacy and safety of PEGASYS in patients with HBeAg positive chronic hepatitis B (CHB).Patients who received treatment with PEGASYS, and…
- Trial name
- NCT00927082
- Testing
- peginterferon alfa-2a [Pegasys]
- Where
- 31 sites in Australia, Brazil and 8 more
- Volunteers
- 383 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C, HIV Infections
Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous Therapies
To determine the efficacy and safety of Peginterferón alfa-2a (40 KD) plus Ribavirin in patients who have relapsed or not responded to a previous suboptimal therapy based in Interferon.
- Trial name
- PILOT-NR (NCT00530972)
- Testing
- Peginterferon alfa-2a plus ribavirin adjusted to body weight
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Hospital Carlos III, Madrid
Hepatitis C, Chronic, Hepatitis C
Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)
Participants will receive PegIntron injection pen (Peginterferon alfa-2b) and Rebetol (Ribavirin) combination therapy as their usual medical treatment.
- Trial name
- NCT00725205
- Testing
- PegIntron (Peginterferon alfa-2b), Rebetol (Ribavirin)
- Volunteers
- 294 people
- Sponsor
- Merck Sharp & Dohme LLC
Portal Hypertension
Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir
Portal hypertension is a common pathology in chronic liver disease, particularly in liver cirrhosis. Hepatitis B Virus (HBV) is one of most etiologies of liver cirrhosis in China.
- Trial name
- NCT02945956
- Testing
- Entecavir, Entecavir + Fuzheng Huayu
- Where
- 3 sites in China
- Volunteers
- 192 people
- Sponsor
- ShuGuang Hospital
Chronic Hepatitis C Infection
Herpes Simplex Type 1 Suppression in Hepatitis C
The purpose of this study is to examine the effects of valacyclovir in patients who have chronic hepatitis C, antibodies to herpes simplex type 1 infection but do not have antibodies to herpes simplex type 2 infection.
- Trial name
- HSV1/HCV (NCT01580995)
- Testing
- Valacyclovir
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Hepatitis B, Chronic
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B.
Find a possible association between Fibronectin type Ⅲ domain containing protein 5 \ Irsin (FNDC5 rs3480) gene single nucleotide polymorphism with chronic hepatitis B and the distribution of its alleles, in relation to many…
- Trial name
- NCT06023745
- Testing
- genotyping
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Sohag University
Liver Insufficiency, Kidney Failure, Chronic
Quantification of Drugs and Their Degradation Products
The study includes two study parts in which blood is collected from the patients. Study part A (observational study, already received positive ethics committee vote; Our sign: 12-330): Use of blood samples gathered during routine…
- Conditions
- Liver Insufficiency, Kidney Failure, Chronic, Obesity, Pregnancy
- Trial name
- NCT01828372
- Testing
- additional blood withdrawals
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- University of Cologne
Chronic Hepatitis C, Menopause
Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)
The cohort of post-menopausal women represents a group of very-difficult-to-treat patients in whom a more powerful approach is required in order to improve the disappointing response rate.
- Trial name
- MEN_BOC (NCT01457937)
- Testing
- Pegylated Interferon, Ribavirin, Boceprevir
- Where
- Italy
- Volunteers
- 240 people
- Sponsor
- University of Modena and Reggio Emilia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.